cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Cagrilintide lowers bodyweight through brain

Your PlexusDx provider can offer specific meal guides tailored to your genetic profile and tolerance timeline

There are currently four GLP-1 receptor agonists approved for use in United States and five approved for use in the European Union (Table 1): exenatide twice daily, liraglutide once daily, exenatide once weekly, albiglutide once weekly, and lixisenatide once daily (available in Europe)

They pursue additional years of training, learning to identify and treat the root causes of illness, such as gut dysfunction, inflammation, nutrient deficiencies, hormone imbalances, toxins, and chronic stress- rather than simply managing symptoms with medication

The 2025 American College of Rheumatology guidelines for SLE treatment and the 2025 EULAR recommendations for lupus nephritis both acknowledge the potential role of metabolic therapies including GLP-1 medications

Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1